CCEL · CIK 0000862692 · operating
Cryo-Cell International operates in cellular preservation and regenerative medicine, specializing in the collection, processing, and cryogenic storage of umbilical cord blood stem cells for family use. The company's core service involves preserving cord blood immediately after delivery, maintaining these cells in long-term frozen storage for potential future therapeutic applications. The company also offers cord tissue preservation, which stores sections of umbilical cord tissue as a source of mesenchymal stem cells used in regenerative medicine treatments.
The company manufactures and markets the PrepaCyte CB processing system, a medical device used to process umbilical cord blood stem cells according to clinical protocols. Revenue is generated through direct-to-consumer marketing of cord blood and tissue preservation services to expectant parents, supplemented by a distribution channel through healthcare professionals including obstetricians, pediatricians, childbirth educators, and certified nurse-midwives.
Based in Oldsmar, Florida, Cryo-Cell International operates with approximately 82 full-time employees. The company was incorporated in Delaware in 1989 and maintains NYSE listing status.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.30 | $-0.30 | -700.0% | |
| 2024 | $0.05 | $0.05 | +104.4% | |
| 2023 | $-1.14 | $-1.14 | -445.5% | |
| 2022 | $0.33 | $0.33 | +32.0% | |
| 2021 | $0.25 | $0.26 | -44.4% | |
| 2020 | $0.45 | $0.48 | +66.7% | |
| 2019 | $0.27 | $0.29 | +345.5% | |
| 2018 | $-0.11 | $-0.11 | -136.7% | |
| 2017 | $0.30 | $0.33 | +287.5% | |
| 2016 | $-0.16 | $-0.16 | -119.3% | |
| 2015 | $0.83 | $0.85 | +1560.0% | |
| 2014 | $0.05 | $0.05 | — | |
| 2013 | $0.00 | $0.00 | +100.0% | |
| 2012 | $-0.56 | $-0.56 | -211.1% | |
| 2011 | $-0.18 | $-0.18 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-11-30 | 2026-02-27 | 0001193125-26-083096 | SEC ↗ |
| 2024-11-30 | 2025-02-28 | 0000950170-25-030138 | SEC ↗ |
| 2023-11-30 | 2024-02-28 | 0000950170-24-022275 | SEC ↗ |
| 2022-11-30 | 2023-02-28 | 0000950170-23-005220 | SEC ↗ |
| 2021-11-30 | 2022-02-22 | 0000950170-22-001637 | SEC ↗ |
| 2020-11-30 | 2021-03-01 | 0001564590-21-009945 | SEC ↗ |
| 2019-11-30 | 2020-02-28 | 0001193125-20-056695 | SEC ↗ |
| 2018-11-30 | 2019-02-28 | 0001193125-19-057945 | SEC ↗ |
| 2017-11-30 | 2018-02-28 | 0001193125-18-064199 | SEC ↗ |
| 2016-11-30 | 2017-02-28 | 0001193125-17-062739 | SEC ↗ |
| 2015-11-30 | 2016-02-29 | 0001193125-16-485790 | SEC ↗ |
| 2014-11-30 | 2015-03-02 | 0001193125-15-073665 | SEC ↗ |
| 2013-11-30 | 2014-02-28 | 0001193125-14-077783 | SEC ↗ |
| 2012-11-30 | 2013-02-28 | 0001193125-13-084813 | SEC ↗ |
| 2011-11-30 | 2012-02-28 | 0001193125-12-085810 | SEC ↗ |
| 2010-11-30 | 2011-02-28 | 0001193125-11-049956 | SEC ↗ |
| 2009-11-30 | 2010-03-01 | 0001193125-10-044939 | SEC ↗ |
| 2008-11-30 | 2009-03-02 | 0001193125-09-042762 | SEC ↗ |
| 2007-11-30 | 2008-02-11 | 0001193125-08-025633 | SEC ↗ |